Full-Time

Area Sales Manager

Updated on 9/4/2026

PROCEPT BioRobotics

PROCEPT BioRobotics

501-1,000 employees

Robotic system enabling Aquablation BPH treatment

Compensation Overview

£101.4k/yr

United Kingdom

In Person

Must be able to travel extensively within the United Kingdom (up to 80%).

Bachelor's

Category
Sales & Account Management (1)
Required Skills
Sales
Inventory Management
Forecasting
FDA Regulations
Marketing
Customer Service

Get referred to PROCEPT BioRobotics

See people who can refer or advise you

Requirements
  • Bachelor’s degree or equivalent work experience
  • Ability to travel extensively in the United Kingdom up to 80%
  • Ability to attend internal and external meetings internationally if required
  • A minimum of five years of experience in medical sales within the Urology space or Operating Room
  • Experience selling capital equipment and the ability to sell innovative products
  • Experience introducing market development programs to hospitals and/or physician practices
  • Strong local relationships within the healthcare community in specified geographic area
  • Leadership and commercial skills as demonstrated through past professional performance
Responsibilities
  • Meet/exceed quarterly sales quota for the defined territory
  • Maintain a monthly and quarterly territory plan that outlines territory sales objectives and areas of opportunity and growth
  • Provide weekly/monthly forecasts for the defined territory
  • Provide medical professionals with product support information and training on the use of Company products and with staff education, in-services, and technical troubleshooting
  • Effectively communicate AquaBeam’s value proposition to customers
  • Effectively manage transition of initial sale and installation to the Aquablation sales team to drive procedural volume and growth
  • Develop initial contact with CEO and senior hospital administrators
  • Manage the complex sales process of the Aquabeam System into new and existing hospitals
  • Build clinical and administrative support through technical presentations, executive meetings, and marketing events
  • Communicate current market conditions and recommend improvements to the commercial process
  • Build and maintain relationships with key customers and KOLs within region
  • Partner closely with the Marketing team to identify and prioritize customers for higher-level corporate relationships
  • Attend local, National and European level exhibitions and meetings when required
  • Partner with the Marketing team to organize and execute local activities and events for key customers and KOLs
  • Partner with the Customer Service team to meet and exceed customer expectations
  • Partner with the International Sales team and the Finance team to ensure all required sales reporting forms are completed and submitted on time
  • Maintain records in the PROCEPT CRM system on contacts, facilities & sales channel process
  • Provide weekly/monthly capital pipeline updates through defined systems
  • Provide support in the resolution of product complaints and/or safety issues
  • Proactively support organizational goals and objectives, policies and procedures, Good Manufacturing Practices, and FDA regulations including strict compliance with AquaBeam’s Customer Relationship and the Sunshine Act policies
  • Responsible for compliance with Quality System requirements applicable to tasks performed by the holder of this job function
  • Maintain a professional and credible image with key physicians, consultants, suppliers, and teammates
  • Establish and maintain credentials to enter and work in hospitals and other medical facilities as required by facility requirements
  • Manage travel and expenses per approved budget
  • Maintain Emergency Stock with adequate par levels to be reconciled quarterly
  • Maintain trained status for, and comply with, all relevant aspects of the PROCEPT BioRobotics Quality Management System to ensure product and support regulatory compliance
  • Maintain local requirements for Industry Accreditation
  • Understand and adhere to the PROCEPT BioRobotics Quality & EHS Policies

PROCEPT BioRobotics develops robotic medical devices for treating enlarged prostate (BPH). Its flagship AquaBeam Robotic System enables Aquablation therapy, a minimally invasive procedure that removes prostate tissue using a waterjet guided by real-time imaging and robotics to achieve precise, reproducible tissue removal. The system is designed for use by urologists in hospitals and clinics, and the company monetizes through the sale of the AquaBeam system, ongoing revenue from disposable procedure components, and training and support services for providers. Compared with competitors, PROCEPT focuses on a controlled, image-guided robotic approach that aims for predictable outcomes and fewer complications, and its technology has gained recognition in clinical practice guidelines. The company’s goal is to improve patient quality of life by delivering accurate, efficient, and minimally invasive BPH treatment that reduces urinary symptoms using a repeatable surgical workflow.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2009

Get referred to PROCEPT BioRobotics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 4, 2026 Q2 revenue reached $94.5 million, up 19% year over year.
  • June 24, 2026 Evercore initiated coverage at Outperform with a $30 price target.
  • 2026 guidelines endorsements and Water IV enrollment support stronger hospital adoption and replacement demand.

What critics are saying

  • February 2026 securities class action alleges bulk-discount channel stuffing and inventory inflation through February 25, 2026.
  • August 2026 Q2 guidance lowered U.S. procedures to 54,000-56,000, signaling weaker legacy account utilization.
  • PROCEPT remains heavily dependent on BPH; failed prostate-cancer expansion leaves Aquablation a single-product story.

What makes PROCEPT BioRobotics unique

  • Aquablation combines imaging, robotics, and waterjet tissue removal for BPH treatment.
  • EAU and AUA guidelines in 2026 strengthened Aquablation recommendations across broader prostate sizes.
  • May 2026 WATER IV trials expanded PROCEPT into prostate cancer research, widening the platform.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Company Match

401(k) Retirement Plan

Paid Vacation

Paid Parental Leave

Paid Holidays

Wellness Program

Gym Membership

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Investors Hangout
Sep 3rd, 2026
PROCEPT faces legal storm over sales practices missteps.

PROCEPT faces legal storm over sales practices missteps. Investors take aim: A legal showdown on the horizon. There's a brewing storm over at PROCEPT BioRobotics - ticker NASDAQ:PRCT if you're tracking. These folks are knee-deep in a securities class action lawsuit from investors who've taken a financial wallop. The lawsuits are triggered by allegations of shady sales techniques that artificially bumped up their unit sales numbers, leaving some shareholders with substantial losses. From February 2024 to February 2026, investors unknowingly danced to the company's tune. However, as time wore on, those tunes turned out to be offbeat, revealing an orchestra of unsustainable sales maneuvers that included late sales pushes and bulk discounts that piled up inventories way higher than actual demand. Let that sink in - 10,000 excess units gathering dust while they fed off tomorrow's customer orders to pretty up today's books. Shades of misconduct: behind the padded sales numbers. Now, let's tear into what was happening under PROCEPT's hood. It's alleged that their "growth story" wasn't exactly telling the whole truth. Imagine stacking unit sales high through enticing bulk discounts, daring customers to fill their shelves with goods they didn't need. All this made those quarterly numbers look peachy-keen, until the truth slyly slipstreamed into their financial results. This rampant inventory padding came to light with slashed sales predictions, first in August 2025 and again when they couldn't shake their numbers back into line by November. Each belly flop in forecast pointed to something stinking in the numbers game. By February 2026, the cold, hard truth punched through when PROCEPT finally fessed up to the inventory bloat. Stock price vs. Reality: A lesson in transparency. Here's the kicker: this inventory circus had a real price tag for PROCEPT's investors. The stock nosedived by $22.06, which, if you're counting, is a hefty 48% drop from its August 2025 stature. Investors learned the hard way that what's shiny on paper might just peel off in reality. Reed Kathrein from Hagens Berman didn't mince words: "We're focused on whether PROCEPT may have intentionally pulled-in sales from future quarters to make it seem like the company was meeting expectations and, if so, whether the company had been sufficiently transparent in its investor communications." It's a classic case of transparency - or lack thereof - coming home to roost. Did PROCEPT play a slick game of smoke and mirrors to dodge Wall Street's ire? That's the $64,000 question, and it's got the legal eagles sharpening their talons. * Surprise underperformance in core product sales. * Accusations of hiding the real financial picture. * Massive decline in stock value, impacting investor trust. Roll up your sleeves, investors: navigating the implications. For all the investors caught in the headlights, there's a glimmer of opportunity. The lawsuit, steered by Hagens Berman Sobol Shapiro LLP, offers an avenue to potentially recuperate some of those hefty losses. The firm is rallying others to join their cause, motivated by the chronicles of bulk discounts and manipulated sales performance that turned into a high-stakes gamble. So, what's the play for anyone in the trenches with PROCEPT stock? Keep those ears to the ground and eyes peeled on the legal process. The allegations are stacked higher than a jittery trader's caffeine intake, and how this navigates through the courts could set precedent, or at least a learning moment for others crafting their fiscal narrative. In a sector where innovation mingles with uncertainty, investors must weigh every disclosed metric as though it might carry a double meaning. Maybe it's about time investors demand robust reporting that captures not just the gloss, but the grit. Navigating this legal quagmire won't be quick or easy, but for folks with losses or those holding the key to more insights, it's a silver lining when you get to call out corporate missteps and get ahead with potential recoveries.

Yahoo Finance
Aug 18th, 2026
Procept BioRobotics CEO buys $498K in shares as stock falls 48% in year

Procept BioRobotics CEO Larry Wood purchased 23,900 shares through The Larry Wood Trust on 7 August 2026, valued at approximately $498,000. The purchase came as the stock traded at $20.85 per share, marginally above the $20.41 market close, whilst shares have declined 48% over the past year. Following the transaction, Wood holds a total beneficial interest of 338,103 shares in the San Jose-based medical technology firm, which has a market capitalisation of $1.2 billion. The company generated $337.3 million in trailing twelve-month revenue whilst posting a net loss of $109.8 million over the same period. Procept BioRobotics develops the AquaBeam Robotic System, which performs Aquablation therapy for treating benign prostatic hyperplasia in male patients.

Business Wire
Aug 11th, 2026
PRCT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP files Class Action lawsuit against PROCEPT BioRobotics Corporation and announces opportunity for investors with substantial losses to lead Clas...

PRCT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP files Class Action lawsuit against PROCEPT BioRobotics Corporation and announces opportunity for investors with substantial losses to lead Class Action lawsuit. SAN DIEGO-(BUSINESS WIRE)-Robbins Geller Rudman & Dowd LLP announces that purchasers of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) common stock between February 28, 2024 and February 25, 2026, both dates inclusive (the "Class Period"), have until September 22, 2026 to seek appointment as lead plaintiff of the Procept class action lawsuit. Captioned Operating Engineers Construction Industry and Miscellaneous Pension Fund v. PROCEPT BioRobotics Corporation, No. 26-cv-07691 (N.D. Cal.), the Procept class action lawsuit charges Procept as well as certain of Procept's top current and former executive officers with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Procept class action lawsuit, please provide your information here: You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at [email protected]. CASE ALLEGATIONS: Procept is a medical technology company that sells surgical devices used in the treatment of benign prostatic hyperplasia. The Procept class action lawsuit alleges that defendants throughout the Class Period made materially false and/or misleading statements because they failed to disclose the following adverse facts pertaining to Procept's business, operations, and financial condition, which were known to defendants or recklessly disregarded by them as follows: (i) that, during the Class Period, Procept had utilized an extensive discount program designed to incentivize its customers to place bulk orders in excess of procedure demand; (ii) that Procept's undisclosed discount program had artificially and unsustainably inflated Procept's reported U.S. handpiece unit sales and revenues by pulling forward sales at the expense of future periods; (iii) that Procept's undisclosed discount program had caused customer handpiece orders to materially exceed underlying procedure demand throughout the Class Period and that this differential had materially grown over time; (iv) that Procept's consistent surplus of U.S. handpiece unit sales relative to performed procedures had created a glut of field inventory and overstocking amongst Procept's customer base, amounting to more than 10,000 excess units by the end of the Class Period; (v) that, as a result of (i)-(iv) above, defendants' representations during the Class Period regarding Procept's handpiece unit sales and the utilization of Procept's field Systems were materially overstated; (vi) that, as a result of (i)-(v) above, Procept was acutely exposed to material undisclosed risks of significant operational and financial harm; and (vii) that, as a result of (i)-(vi) above, Procept was unable to achieve its stated 2025 handpiece sales and revenue guidance and such guidance lacked a reasonably achievable factual basis. The Procept class action lawsuit further alleges that on August 6, 2025, Procept announced earnings for its second fiscal quarter of 2025, revealing that Procept had only sold approximately 12,750 handpieces in the United States during the quarter. During Procept's earnings call, defendant Kevin Waters reported that Procept expected to ship approximately 13,350 units in the following quarter, significantly below consensus estimates of more than 13,840 units. Procept's quarterly handpiece sales guidance also implied that Procept would need to grow handpiece sales by approximately 25% year-over-year in the fourth quarter in order to meet Procept's annual unit sales guidance. In addition, defendant Reza Zadno revealed that Procept was eliminating the role of Chief Commercial Officer in order to "strengthen" Procept's "commercial execution." On this news, the price of Procept stock fell approximately 16% over a two-day trading period. Then, on November 4, 2025, Procept announced earnings results for its third fiscal quarter of 2025, revealing that Procept had only sold 13,225 handpieces during the quarter, which missed Procept's sales guidance issued during the prior quarter. During the corresponding conference call, defendant Kevin Waters further revealed that Procept was reducing its annual handpiece sales guidance by 1,000 units, down from 53,000 units to 52,000 units to allow for the "optimization of field inventory." Defendant Larry L. Wood further admitted that Procept had not "been managing customer inventory by establishing par levels" and that some customers were "probably carrying too much inventory." On this news, the price of Procept stock fell more than 10% over a two-day trading period. Finally, on February 25, 2026, Procept announced earnings results for its fourth fiscal quarter and year ending December 31, 2025. Procept revealed that handpiece sales had materially exceeded procedures in every quarter since the first fiscal quarter of 2023, a differential which had consistently grown over time, ultimately resulting in cumulative excess field inventory of more than 10,000 units. Procept further revealed that quarterly handpiece unit sales in the United States had declined significantly from 13,225 units in the third quarter to 9,400 units, representing a sequential decline of nearly 30%. On this news, the price of Procept stock fell more than 18% over a two-day trading period. The plaintiff is represented by Robbins Geller, which has extensive experience in prosecuting investor class actions including actions involving financial fraud. You can view a copy of the complaint by clicking here. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Procept common stock during the Class Period to seek appointment as lead plaintiff in the Procept class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Procept class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Procept class action lawsuit. An investor's ability to share in any potential future recovery of the Procept class action lawsuit is not dependent upon serving as lead plaintiff. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder rights litigation. Its Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks its fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors - $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever - $7.2 billion - in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of its offices. Contacts. Robbins Geller Rudman & Dowd LLP Ken Dolitsky Michael Albert 655 W. Broadway, Suite 1900, San Diego, CA 92101 800/851-7783 [email protected] More News From Robbins Geller Rudman & Dowd LLP SAN DIEGO-( BUSINESS WIRE )-The case alleges Capricor Therapeutics and certain of its top executives made false and/or misleading statements to investors... SAN DIEGO-( BUSINESS WIRE )-The case alleges Bloom Energy and certain of its top executives made false and/or misleading statements to investors... SAN DIEGO-( BUSINESS WIRE )-The case alleges Wix and certain of its executives made false and/or misleading statements to investors...

NewMediaWire
Aug 6th, 2026
Kaplan Fox urges investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) with significant losses to seek a leadership role before September 22, 2026.

Kaplan Fox urges investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) with significant losses to seek a leadership role before September 22, 2026. Aug. 5, 2026 7:30 PM ET Source: Kaplan Fox NEW YORK, NY - August 5, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation ("PROCEPT" or the "Company") (NASDAQ: PRCT) on behalf of all purchasers of PROCEPT common stock between February 28, 2024 and February 25, 2026 (the "Class Period"). If you are an investor in PROCEPT and have suffered losses, you may CLICK HERE to contact NewMediaWire LLC. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than September 22, 2026 to serve as a lead plaintiff for the purported class. If you have losses NewMediaWire LLC encourage you to contact NewMediaWire LLC to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery. The complaint alleges that contrary to defendants' Class Period assurances that the "differential" between handpiece unit sales and procedures had "remained relatively consistent," PROCEPT's discount program had caused handpiece orders to materially exceed procedures in every quarter during the Class Period. According to the complaint, these undisclosed sales tactics artificially inflated PROCEPT's reported U.S. handpiece unit sales and revenues by pulling forward demand at the expense of future periods. WHY CONTACT KAPLAN FOX? Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented. Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America - the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act - $800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch. For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes. If you have any questions about this Notice, your rights, or your interests, please contact: Laurence D. King KAPLAN FOX & KILSHEIMER LLP 1999 Harrison Street, Suite 1501 Oakland, California 94612 (415) 772-4704 [email protected] Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.

Mangalore Mirror
Aug 4th, 2026
INVESTOR ALERT: Pomerantz law Firm reminds investors with losses on their investment in PROCEPT BioRobotics Corporation of class action lawsuit and upcoming deadlines - PRCT.

INVESTOR ALERT: Pomerantz law Firm reminds investors with losses on their investment in PROCEPT BioRobotics Corporation of class action lawsuit and upcoming deadlines - PRCT. 2 2 minutes read NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) - Pomerantz LLP announces that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation ("Procept" or the "Company") (NASDAQ: PRCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. US news subscription The class action concerns whether Procept and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. You have until September 22, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Procept securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com. On August 6, 2025, Procept announced earnings for its second fiscal quarter of 2025, revealing that Procept had only sold approximately 12,750 handpieces in the United States during the quarter. During Procept's earnings call, Chief Financial Officer Kevin Waters reported that Procept expected to ship approximately 13,350 units in the following quarter, significantly below consensus estimates of more than 13,840 units. Procept's quarterly handpiece sales guidance also implied that Procept would need to grow handpiece sales by approximately 25% year-over-year in the fourth quarter in order to meet Procept's annual unit sales guidance. In addition, then-Chief Executive Officer Reza Zadno revealed that Procept was eliminating the role of Chief Commercial Officer in order to "strengthen" Procept's "commercial execution." On this news, Procept's stock price fell approximately 16% over a two-day trading period. Then, on November 4, 2025, Procept announced earnings results for its third fiscal quarter of 2025, revealing that Procept had only sold 13,225 handpieces during the quarter, which missed Procept's sales guidance issued during the prior quarter. During the corresponding conference call, CFO Waters further revealed that Procept was reducing its annual handpiece sales guidance by 1,000 units, down from 53,000 units to 52,000 units to allow for the "optimization of field inventory." CEO Larry L. Wood further admitted that Procept had not "been managing customer inventory by establishing par levels" and that some customers were "probably carrying too much inventory." On this news, Procept's stock price fell more than 10% over a two-day trading period. Finally, on February 25, 2026, Procept announced earnings results for its fourth fiscal quarter and year ending December 31, 2025. Procept revealed that handpiece sales had materially exceeded procedures in every quarter since the first fiscal quarter of 2023, a differential which had consistently grown over time, ultimately resulting in cumulative excess field inventory of more than 10,000 units. Procept further revealed that quarterly handpiece unit sales in the United States had declined significantly from 13,225 units in the third quarter to 9,400 units, representing a sequential decline of nearly 30%. On this news, Procept's stock price fell more than 18% over a two-day trading period. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes.